ABSTRACT
Phytosterols constitute a class of natural products that are an important component of diet and have vast applications in foods, cosmetics, and herbal medicines. With many and diverse isolated structures in nature, they exhibit a broad range of biological and pharmacological activities. Among over 200 types of phytosterols, stigmasterol and ß-sitosterol were ubiquitous in many plant species, exhibiting important aspects of activities related to neurodegenerative diseases. Hence, this mini-review presented an overview of the reported studies on selected phytosterols related to neurodegenerative diseases. It covered the major phytosterols based on biosynthetic considerations, including other phytosterols with significant in vitro and in vivo biological activities.
Subject(s)
Brain/metabolism , Neurodegenerative Diseases/prevention & control , Phytosterols/therapeutic use , Phytotherapy/methods , Plants, Medicinal/chemistry , Brain/pathology , Humans , Molecular Structure , Neurodegenerative Diseases/metabolism , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacokinetics , Neuroprotective Agents/therapeutic use , Phytosterols/chemistry , Phytosterols/pharmacokinetics , Sitosterols/chemistry , Sitosterols/pharmacokinetics , Sitosterols/therapeutic use , Stigmasterol/chemistry , Stigmasterol/pharmacokinetics , Stigmasterol/therapeutic useABSTRACT
Seasonal and pandemic influenza infections are serious threats to public health and the global economy. Since antigenic drift reduces the effectiveness of conventional therapies against the virus, herbal medicine has been proposed as an alternative. Fritillaria thunbergii (FT) have been traditionally used to treat airway inflammatory diseases such as coughs, bronchitis, pneumonia, and fever-based illnesses. Herein, we used a network pharmacology-based strategy to predict potential compounds from Fritillaria thunbergii (FT), target genes, and cellular pathways to better combat influenza and influenza-associated diseases. We identified five compounds, and 47 target genes using a compound-target network (C-T). Two compounds (beta-sitosterol and pelargonidin) and nine target genes (BCL2, CASP3, HSP90AA1, ICAM1, JUN, NOS2, PPARG, PTGS1, PTGS2) were identified using a compound-influenza disease target network (C-D). Protein-protein interaction (PPI) network was constructed and we identified eight proteins from nine target genes formed a network. The compound-disease-pathway network (C-D-P) revealed three classes of pathways linked to influenza: cancer, viral diseases, and inflammation. Taken together, our systems biology data from C-T, C-D, PPI and C-D-P networks predicted potent compounds from FT and new therapeutic targets and pathways involved in influenza.
Subject(s)
Antiviral Agents/chemistry , Fritillaria/chemistry , Orthomyxoviridae/drug effects , Anthocyanins/chemistry , Anthocyanins/pharmacokinetics , Antiviral Agents/pharmacokinetics , Databases, Chemical/statistics & numerical data , Databases, Genetic/statistics & numerical data , Humans , Pharmacology/methods , Protein Interaction Maps , Sitosterols/chemistry , Sitosterols/pharmacokinetics , Systems Biology/methodsABSTRACT
A rapid and sensitive ultra high performance liquid chromatography with tandem mass spectrometry method was established and validated for simultaneous determination of thirteen bioactive components (gallic acid, protocatechuic acid, puerarin, p-hydroxycinnamic acid, daidzin, ononin, daidzein, naringenin, genistein, apigenin, formononetin, biochanin A, and ß-sitosterol) of Radix Puerariae extract in rat plasma and tissues. The plasma and tissues samples were pretreated by protein precipitation extraction, and umbelliferone and rutin were used as internal standards. Sample separation was performed on a ZORBAX RRHD Eclipse plus C18 column (2.1 mm × 50 mm, 1.8 µm, Agilent) with a mobile phase consisting of methanol-water (containing 0.1% formic acid). The mass spectrometry analysis was conducted in positive and negative ionization modes with multiple reaction monitoring. The lower limit of quantitation range for the 13 analytes was 0.2-35 ng/mL. The intra- and inter-day precision of all the analytes were less than 10.92%, with an accuracy ranging from -13.10 to 11.96%. Both the recovery and matrix effect were within acceptable limits. This method was successfully applied to pharmacokinetic and tissue distribution study of the 13 bioactive components in rats after oral administration of R. Puerariae extract.
Subject(s)
Apigenin/pharmacokinetics , Drugs, Chinese Herbal/pharmacokinetics , Genistein/pharmacokinetics , Isoflavones/pharmacokinetics , Pueraria/chemistry , Sitosterols/pharmacokinetics , Administration, Oral , Animals , Apigenin/administration & dosage , Apigenin/analysis , Chromatography, High Pressure Liquid , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/analysis , Genistein/administration & dosage , Genistein/analysis , Isoflavones/administration & dosage , Isoflavones/analysis , Molecular Structure , Rats , Rats, Sprague-Dawley , Sitosterols/administration & dosage , Sitosterols/analysis , Tandem Mass Spectrometry , Tissue DistributionABSTRACT
Lecithin-linker microemulsions are formulations produced with soybean lecithin in combination with a highly lipophilic (lipophilic linker) and highly hydrophilic (hydrophilic linkers) surfactant-like additives. In this work, lecithin-linker systems were formulated to produce self-emulsifying delivery systems for ß-carotene and ß-sitosterol. The concentration of the lipophilic linker, sorbitan monooleate, was adjusted to minimize the formation of liquid crystals. The concentration of hydrophilic linkers, decaglyceryl caprylate/caprate and PEG-6-caprylic/capric glycerides, was gradually increased (scanned) until single phase clear microemulsions were obtained. For these scans, the oil (ethyl caprate) to water ratio was set to 1. The single phase, clear microemulsions were diluted with fed-state simulated intestinal fluid (FeSSIF) and produced stable emulsions, with drop sizes close to 200 nm. Using pseudo-ternary phase diagrams to evaluate the process of dilution of microemulsion preconcentrates (mixtures of oil, lecithin and linkers with little or no water) with FeSSIF, it was determined that self-emulsifying systems are obtained when the early stages of the dilution produce single phase microemulsions. If liquid crystals or multiple phase systems are obtained during those early stages, then the emulsification yields unstable emulsions with large drop sizes. An in vitro permeability study conducted using a Flow-Thru Dialyzer revealed that stable emulsions with drop sizes of 150-300 nm produce large and irreversible permeation of ß-carotene to sheep intestine. On the other hand, unstable emulsions produced without the linker combination separated in the dialyzer chamber.
Subject(s)
Dietary Supplements , Drug Carriers/chemistry , Lecithins/chemistry , Sitosterols/administration & dosage , Surface-Active Agents/chemistry , beta Carotene/administration & dosage , Animals , Chemistry, Pharmaceutical , Emulsions , Hydrophobic and Hydrophilic Interactions , In Vitro Techniques , Jejunum/metabolism , Molecular Structure , Permeability , Phase Transition , Sheep , Sitosterols/pharmacokinetics , Glycine max/chemistry , Surface Tension , beta Carotene/pharmacokineticsABSTRACT
Recent findings suggest that mitochondrial membrane fluidity could influence mitochondrial energy metabolism. ß-sitosterol (BS) is a common plant sterol that is prevalent in plant oils, nuts, cereals and plant food products. Its chemical structure is very similar to that of cholesterol. As a cholesterol analog, BS is highly lipid soluble and largely resides in the membranes of cells or organelles where it may have an influence on the membrane fluidity. The present study reports that, with the cholesterol chelator 2-hydroxypropyl-ß-cyclodextrin (HPßCD) as its carrier, BS is able to increase the fluidity of the inner mitochondrial membrane (IMM) without affecting the fluidity of the outer mitochondrial membrane (OMM), and consequently to increase the mitochondrial membrane potential (∆Ψm) and mitochondrial ATP content. It has been previously proposed that a therapeutical boost in adenosine triphosphate (ATP) levels in mitochondria may be beneficial for neurodegenerative diseases such as Alzheimer's disease (AD). Given that dietary administration of plant sterols could increase brain BS concentrations, these results may provide a better understanding of the beneficial effects of plant sterol-enriched nutrients on neurodegenerative diseases such as AD.
Subject(s)
Hypolipidemic Agents/pharmacokinetics , Membrane Fluidity/drug effects , Mitochondria/metabolism , Mitochondrial Membranes/metabolism , Sitosterols/pharmacokinetics , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Cell Line , Humans , Hypolipidemic Agents/pharmacology , Sitosterols/pharmacologyABSTRACT
Recently, increasing evidence has linked high cholesterol to the pathogenesis of Alzheimer's disease (AD), suggesting that cholesterol may be a target for developing new compounds to prevent or treat AD. Plant sterols, a group of sterols enriched in plant oils, nuts, and avocados, have the structure very similar to that of cholesterol, and have been widely used to reduce blood cholesterol. Due to their cholesterol-lowering property, plant sterols such as ß-sitosterol may also influence cholesterol-depending functions including its role in AD development. Using human platelets, a type of peripheral blood cells containing the most circulating amyloid precursor protein (APP), this study investigated the effect of ß-sitosterol on high cholesterol-induced secretion of ß amyloid protein (Aß). It was found that ß-sitosterol effectively inhibited high cholesterol-driven platelet Aß release. In addition, ß-sitosterol prevented high cholesterol-induced increase of activities of ß- and γ-secretase, two APP cleaving enzymes to generate Aß. Additional experiments showed that high cholesterol up-regulated lipid raft cholesterol. This effect of cholesterol could be suppressed by ß-sitosterol. These findings suggest that ß-sitosterol is able to inhibit high cholesterol-induced Aß release probably through maintenance of membrane cholesterol homeostasis. Given that dietary plant sterols have the potential of penetrating the blood-brain barrier (BBB), these data suggest that plant sterols such as ß-sitosterol may be useful in AD prevention.
Subject(s)
Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Blood Platelets/metabolism , Sitosterols/pharmacology , Adult , Alzheimer Disease/blood , Alzheimer Disease/prevention & control , Amyloid Precursor Protein Secretases/metabolism , Blood-Brain Barrier/metabolism , Cholesterol/blood , Female , Humans , Male , Sitosterols/pharmacokineticsABSTRACT
Foods containing plant sterol or stanol esters can be beneficial in lowering LDL-cholesterol concentration, a major risk factor for CVD. The present study examined whether high dietary intake of rapeseed oil (RSO) derived plant sterol and stanol esters is associated with increased levels of these components in brain tissue of homozygous and heterozygous Watanabe rabbits, an animal model for familial hypercholesterolemia. Homozygous animals received either a standard diet, RSO stanol or RSO sterol ester while heterozygous animals were additionally fed with 2 g cholesterol/kg to the respective diet form for 120 d (n 9 for each group). Concentrations of cholesterol, its precursor lathosterol, plant sterols and stanols in brain and additionally in liver and plasma were determined by highly sensitive GC-MS. High-dose intake of RSO derived plant sterols and stanols resulted in increased levels of these components in plasma and liver. In brain a limited uptake of plant sterols and stanols was proven, indicating that these compounds passed the blood-brain barrier and may be retained in the brain tissue of Watanabe rabbits. Plant stanol ester feeding lowered plant sterol levels in brain, liver, and plasma. Cholesterol synthesis in brain, indicated by lathosterol, a local surrogate cholesterol synthesis marker, does not seem to be affected by plant sterol or stanol ester feeding. We conclude that high dose intake of plant sterol and stanol esters in Watanabe rabbits results in elevated concentrations of these components not only in the periphery but also in the central nervous system.
Subject(s)
Brain/metabolism , Phytosterols/pharmacokinetics , Plant Oils/chemistry , Sitosterols/pharmacokinetics , Animal Feed/analysis , Animal Nutritional Physiological Phenomena , Animals , Blood-Brain Barrier , Cholesterol/metabolism , Disease Models, Animal , Fatty Acids, Monounsaturated , Female , Heterozygote , Homozygote , Hyperlipoproteinemia Type II/metabolism , Liver/metabolism , Male , Phytosterols/blood , Rabbits , Rapeseed Oil , Sitosterols/bloodABSTRACT
BACKGROUND/PURPOSE: Small bowel transplantation impairs enteric function and causes malabsorption of cholesterol and bile acids. Growth hormone stimulates intestinal absorptive function. The authors hypothesized that long-term growth hormone therapy could improve absorption of bile acids and cholesterol after autotransplantation of the jejunoileum. METHODS: Sixteen pigs with similar food, cholesterol, and fat intake underwent either sham laparotomy or a model of jejunoileal autotransplantation, including extrinsic autonomic denervation, lymphatic interruption, and in situ cold ischemia. Five randomly chosen autotransplanted animals received daily growth hormone treatment for 8 weeks. Serum lipids, absorption, and excretion of cholesterol, bile acids, and fat were determined after 8 weeks. Mucosal morphometrics, proliferation, and enzyme activities were determined. Plasma cholesterol precursors and plant sterols, respective markers of cholesterol synthesis and absorption, were measured after 2 and 8 weeks. RESULTS: After jejunoileal autotransplantation, growth hormone treatment significantly increased body weight gain, cholesterol absorption efficiency from 45.1% to 62.1%, plasma campesterol to cholesterol proportions, and biliary secretion of cholesterol. With or without growth hormone treatment, autotransplantation significantly increased fecal bile acid excretion, plasma cholesterol precursors, fecal bacterially modified neutral sterols, mucosal thickness of the ileum (but not jejunum), and intestinal transit time when compared with sham-operated animals. Crypt cell proliferation, mucosal enzyme activities, and microvilli showed no differences between the groups. CONCLUSIONS: These findings suggest that growth hormone treatment selectively improves cholesterol, but not bile acid absorption, after autotransplantation of the jejunoileum.
Subject(s)
Cholesterol, Dietary/pharmacokinetics , Cholesterol/analogs & derivatives , Cholesterol/pharmacokinetics , Human Growth Hormone/therapeutic use , Ileum/transplantation , Intestinal Absorption/drug effects , Jejunum/transplantation , Malabsorption Syndromes/drug therapy , Phytosterols/pharmacokinetics , Postoperative Complications/drug therapy , Sitosterols/pharmacokinetics , Animals , Autonomic Denervation , Bile Acids and Salts/metabolism , Cholesterol/biosynthesis , Drug Evaluation, Preclinical , Feces/chemistry , Female , Human Growth Hormone/pharmacology , Intestinal Mucosa/enzymology , Intestinal Mucosa/ultrastructure , Laparotomy , Lipids/blood , Malabsorption Syndromes/blood , Malabsorption Syndromes/etiology , Postoperative Complications/blood , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Sus scrofa , Transplantation, AutologousABSTRACT
The effect and mechanism of action of beta-sitosterol beta-D-glucoside (Sit-G) on the in vitro and in vivo nasal absorption of FITC-dextran (molecular weight, 4400; FD-4) in rabbits were studied in comparison with beta-sitosterol (Sit). The FD-4 permeation in the powder dosage form was increased by Sit-G and Sit and related to the uptake of Sit-G and Sit with no changes in the amount of cholesterol in the excised nasal mucosa. The application of Sit and Sit-G increased FD-4 permeation with and without a decrease in transepithelial resistance (TEER), respectively. These results suggested that the mechanism of the enhancement by Sit-G was different from those of Sit and sodium caprate; Sit-G may exert its effects mainly via the transcellular pathway due to perturbation of the mucosal membrane.
Subject(s)
Adjuvants, Pharmaceutic/pharmacology , Dextrans/pharmacokinetics , Fluorescein-5-isothiocyanate/pharmacokinetics , Nasal Mucosa/metabolism , Sitosterols/pharmacology , Absorption/drug effects , Adjuvants, Pharmaceutic/pharmacokinetics , Administration, Intranasal , Animals , Dextrans/administration & dosage , Dosage Forms , Drug Evaluation, Preclinical/methods , Drug Synergism , Fluorescein-5-isothiocyanate/administration & dosage , Fluorescein-5-isothiocyanate/analogs & derivatives , Male , Nasal Mucosa/drug effects , Rabbits , Sitosterols/administration & dosage , Sitosterols/pharmacokineticsABSTRACT
Phytoestrogenic substances have previously been isolated and identified in two alcoholic beverages: bourbon and beer. To delineate the relative potencies of the estrogenic substances of plant origin thus far identified in these commonly consumed alcoholic beverages, we evaluated the ability of biochanin A, beta-sitosterol, genistein, and daidzein to bind to cytosolic estrogen receptor binding sites. The in vitro studies demonstrated that each of the contained substances was capable of effectively competing for cytosolic estrogen receptor binding sites of rat liver and uterus. Further, the two phytoestrogenic constituents of bourbon, beta-sitosterol and biochanin A, were less potent than those present in beer. Given the high concentration of beta-sitosterol in bourbon, we chose to evaluate the estrogenicity of beta-sitosterol in vivo using ovariectomized rats. beta-sitosterol was administered either daily or intermittently at 3 doses, based on amounts previously determined to be present in bourbon. The in vivo studies demonstrated that beta-sitosterol is capable of producing a weak estrogenic effect only at the lowest dose (6.2 micrograms/dl) administered intermittently. These responses suggest that beta-sitosterol may be weakly estrogenic at low doses, but is unable to maintain such an effect at higher doses.